Tirzepatide study for breast cancer survivors with obesity
Treatments studied
Part of Cancer, Hormones & metabolism, Skin clinical trials.
This trial tests if tirzepatide, a weight-loss medication, can help postmenopausal women with hormone-positive breast cancer who have obesity. It aims to improve health outcomes after completing cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You are postmenopausal (either age 60+, or no period for a year, or had ovaries removed, or are on hormone-blocking shots for at least 12 weeks).
- You have had hormone-positive breast cancer (stage 0, I, II, or III) and finished all treatments (surgery, chemo, radiation) at least 12 weeks ago.
- Your body mass index (BMI) is 30 or higher, or 27.5 or higher if you are of Asian ancestry.
- Your insurance will cover tirzepatide, or you can pay for it yourself.
- You are willing to follow study rules and give your consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether the weight-loss drug tirzepatide (Mounjaro) can help prevent breast cancer from coming back in people who are overweight and have a sign of leftover cancer cells in their blood (called MRD-positive). You must have already finished at least one year of hormone therapy for early-stage breast cancer.
This study tests whether tirzepatide, a medication for weight management, affects muscle health in women with obesity. It may help if you are looking for a treatment that preserves muscle while losing weight.
This trial examines how well tirzepatide works for weight loss in people with obesity, and how it's actually used in daily life. It may be an option if you haven't tried other obesity treatments and don't have diabetes.
This study tests if tirzepatide (a weight loss drug) can help women and men with early-stage hormone receptor-positive breast cancer who are overweight or obese. The goal is to see if losing weight can improve outcomes after completing their initial breast cancer treatment.
This study tests if adding a weight loss medication (tirzepatide or semaglutide) during chemotherapy helps people with early-stage endometrial cancer who are overweight or have diabetes. It aims to see if weight loss can improve treatment outcomes.
This trial tests if the weight-loss drug tirzepatide can help people with obesity-related endometrial cancer before their hysterectomy. It may improve surgical outcomes and overall health.
Hear when a new Obesity (Disorder) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.